UBS AM’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21K | Hold |
536
| – | – | ﹤0.01% | 3121 |
|
|
2026
Q1 | $14.5K | Buy |
536
+351
| +190% | +$11.8K | ﹤0.01% | 3214 |
|
|
2025
Q4 | $7.92K | Buy |
+185
| New | +$6.97K | ﹤0.01% | 2899 |
|
|
2022
Q4 | – | Sell |
-21,058
| Closed | -$248K | – | 2711 |
|
|
2022
Q3 | $248K | Hold |
21,058
| – | – | ﹤0.01% | 2547 |
|
|
2022
Q2 | $238K | Hold |
21,058
| – | – | ﹤0.01% | 2539 |
|
|
2022
Q1 | $630K | Hold |
21,058
| – | – | ﹤0.01% | 2370 |
|
|
2021
Q4 | $558K | Hold |
21,058
| – | – | ﹤0.01% | 2512 |
|
|
2021
Q3 | $764K | Sell |
21,058
-9,403
| -31% | -$370K | ﹤0.01% | 2295 |
|
|
2021
Q2 | $1.32M | Buy |
30,461
+122
| +0.4% | +$4.61K | ﹤0.01% | 2049 |
|
|
2021
Q1 | $1.04M | Sell |
30,339
-243
| -0.8% | -$9.62K | ﹤0.01% | 2070 |
|
|
2020
Q4 | $1.07M | Buy |
30,582
+21,087
| +222% | +$610K | ﹤0.01% | 1954 |
|
|
2020
Q3 | $228K | Sell |
9,495
-1,176
| -11% | -$28.9K | ﹤0.01% | 2372 |
|
|
2020
Q2 | $195K | Sell |
10,671
-195
| -2% | -$3.51K | ﹤0.01% | 2393 |
|
|
2020
Q1 | $170K | Buy |
10,866
+2,058
| +23% | +$43.8K | ﹤0.01% | 2324 |
|
|
2019
Q4 | $188K | Sell |
8,808
-580
| -6% | -$11.9K | ﹤0.01% | 2485 |
|
|
2019
Q3 | $176K | Buy |
9,388
+1,112
| +13% | +$23K | ﹤0.01% | 2602 |
|
|
2019
Q2 | $216K | Buy |
8,276
+2,280
| +38% | +$51.5K | ﹤0.01% | 2518 |
|
|
2019
Q1 | $154K | Hold |
5,996
| – | – | ﹤0.01% | 2522 |
|
|
2018
Q4 | $138K | Hold |
5,996
| – | – | ﹤0.01% | 2479 |
|
|
2018
Q3 | $192K | Hold |
5,996
| – | – | ﹤0.01% | 2459 |
|
|
2018
Q2 | $170K | Sell |
5,996
-552
| -8% | -$19.6K | ﹤0.01% | 2506 |
|
|
2018
Q1 | $232K | Buy |
6,548
+3,848
| +143% | +$154K | ﹤0.01% | 2320 |
|
|
2017
Q4 | $105K | Buy |
+2,700
| New | +$103K | ﹤0.01% | 2396 |
|
|
2016
Q2 | – | Sell |
-7,500
| Closed | -$156K | – | 2633 |
|
|
2016
Q1 | $156K | Sell |
7,500
-167,014
| -96% | -$4.12M | ﹤0.01% | 2495 |
|
|
2015
Q4 | $5.29M | Sell |
174,514
-20,916
| -11% | -$634K | 0.01% | 1055 |
|
|
2015
Q3 | $4.83M | Hold |
195,430
| – | – | 0.01% | 1060 |
|
|
2015
Q2 | $6.27M | Hold |
195,430
| – | – | 0.01% | 1008 |
|
|
2015
Q1 | $6.98M | Hold |
195,430
| – | – | 0.01% | 976 |
|
|
2014
Q4 | $4.44M | Sell |
195,430
-3,210
| -2% | -$64.9K | ﹤0.01% | 1063 |
|
|
2014
Q3 | $3.85M | Buy |
198,640
+8,620
| +5% | +$244K | ﹤0.01% | 1090 |
|
|
2014
Q2 | $6.9M | Hold |
190,020
| – | – | 0.01% | 961 |
|
|
2014
Q1 | $7.37M | Hold |
190,020
| – | – | 0.01% | 941 |
|
|
2013
Q4 | $5.42M | Hold |
190,020
| – | – | 0.01% | 989 |
|
|
2013
Q3 | $6.8M | Buy |
190,020
+43,460
| +30% | +$1.59M | 0.01% | 903 |
|
|
2013
Q2 | $4.89M | Buy |
+146,560
| New | +$6.64M | 0.01% | 957 |
|
Other funds holding RIGL
SCM
AC
UBS AM's RIGL Position: Q2 2026 in Review
UBS AM held its Rigel Pharmaceuticals (RIGL) position steady in Q2 2026 at 536 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #3121.
UBS AM first reported a position in RIGL in Q2 2013 and has held it in 35 quarters since. The position peaked at $7.37M in Q1 2014. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.
- UBS AM held 536 shares of Rigel Pharmaceuticals worth $21K as of Q2 2026.
- UBS AM left its Rigel Pharmaceuticals share count unchanged in Q2 2026.
- Rigel Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3121 holding.
- UBS AM first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 35 quarters since.
- UBS AM's Rigel Pharmaceuticals position peaked at $7.37M in Q1 2014.
- 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.